<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426087</url>
  </required_header>
  <id_info>
    <org_study_id>0105467801</org_study_id>
    <nct_id>NCT01426087</nct_id>
  </id_info>
  <brief_title>Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices</brief_title>
  <official_title>Investigator Sponsored Study of Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yunsheng Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main complications of cirrhosis are ascites, esophageal varices and hepatic
      encephalopathy. About 30% to 70% patients with cirrhosis occur esophageal varices, and the
      most common complication is ascites. Somatostatin is used to treat esophageal for a long
      time, otherwise it could aslo prevent ascites. In the study, the investigators explore the
      effects of somatostatin on post-endoscopic portal hemodynamic in cirrhotic patients with
      esophageal gastric varices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      126 patients will be enrolled in the study, 63 subjects will be randomized into the group A
      and the other will be into the group B.

      Group A: endoscopic therapy and somatostatin treatment. Group B: endoscopic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portal vein blood flow volume</measure>
    <time_frame>change from baseline in portal vein blood flow volume after 7 days treatment</time_frame>
    <description>Note:
Portal vein blood flow volume will be measured by doppler ultrasound device.
Values are the mean of three consecutive measurements.
Frequency: PVF will be measured on baseline, day1, day 5 and day 7.
All doppler studies will be carried out by a single experienced examiner who will be blinded to patient allocation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Portal vein diameter (PVD mm)</measure>
    <time_frame>change from baseline in PDV after 7 days treatment</time_frame>
    <description>Portal vein diameter will be measured by doppler ultrasound device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean portal vein blood velocity (PVV cm/s)</measure>
    <time_frame>change from baseline in PVV after 7 days treatment</time_frame>
    <description>PVV will be measured by doppler ultrasound device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascites volume</measure>
    <time_frame>change from baseline after 7 days treatment</time_frame>
    <description>Sonography detecting site: the middle point of the line between navel and the right side of anterior superior iliac spine(ASIS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Esophageal Varices Secondary to Cirrhosis of Liver</condition>
  <arm_group>
    <arm_group_label>endoscopic and somatostatin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>endoscopic therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>giving stilamin 250ug/h after endoscopic therapy for 5 days</description>
    <arm_group_label>endoscopic and somatostatin treatment</arm_group_label>
    <other_name>stilamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic therapy</intervention_name>
    <description>gastroscope plus EIS/EVL/HI</description>
    <arm_group_label>endoscopic therapy</arm_group_label>
    <other_name>antisterone,DHCT,albumin or antibiotics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis with esophageal gastric varices needed endoscopic therapy

          -  Age 18-75 years

          -  Informed written consent

        Exclusion Criteria:

          -  Use of vasoactive drugs 24 hours before endoscopic treatment

          -  Use of B-blocker within 1 week

          -  Previous surgical or endoscopic treatment for esophageal gastric varices

          -  Hepatic encephalopathy,comatose status and any other disease which could not accept
             endoscopic therapy

          -  Gastro-renal vein shunt

          -  Severe hepatic hydrothorax

          -  Hepatocellular carcinoma with portal vein thrombosis

          -  Severe coagulation disorders

          -  Severe active bacteria infection

          -  Severe cardiovascular disease, including a history of acute myocardial
             infarction,heart block, heart failure

          -  Severe renal function insufficiency （Calculated Creatinine Clearance Rate (Ccr)
             ＜30ml/min）

          -  Severe co-morbidity that would affect short-term prognosis

          -  Pregnancy or lactation

          -  Allergy to any ingredient of trial medication

          -  Medical or psychological condition that would not permit the patient to complete the
             study or sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Sh Yang, Pro.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Beijing</city>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Sh Yang, Pro.</last_name>
      <phone>010-66936115</phone>
    </contact>
    <investigator>
      <last_name>Yun Sh Yang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Di Yu Yang, Pro.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yunsheng Yang</investigator_full_name>
    <investigator_title>chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

